Company profile
Anthera Pharmaceuticals, Inc.
OTC: ANTH · Healthcare · Biotechnology
#1021 of 1,418 Healthcare companies by revenue41st-percentile growth
EA Score
——FH —DQ 36GM —SS 38
v0.1 · 25/100 weight · pillars only
↑ listing tenure, filing timeliness · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$26.9M
Employees
21
as of 2026-08-29
Market cap
$2.6k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$145.0k$145.0k2016
Net income-$26.9M-$26.9M2017
Operating income-$36.4M-$36.4M2017
Total assets$3.7M$3.7M2017
Liabilities$9.2M$9.2M2017
Equity-$5.5M-$5.5M2017
Revenue trend
FY2015 – FY2016 · USD
FY15
FY15
FY15
FY15
FY16
FY16
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Anthera Pharmaceuticals, Inc.’s revenue?
Anthera Pharmaceuticals, Inc. booked $145.0k in FY2016 revenue, growing 0.0% year over year — about the middle of the pack among Healthcare companies we track, at a -18533.8% net margin.
Peers · Healthcare
Curative Biosciences, Inc.——ZIVO Bioscience, Inc.——Cannabis Strategic Ventures——VivoSim Labs, Inc.——Sigyn Therapeutics, Inc.——Endonovo Therapeutics, Inc.——Neighbors
Harris →Key facts
CEOPaul F. Truex
SectorHealthcare
IndustryBiotechnology
HeadquartersHouston, TX
ExchangeOTC: ANTH
Employees21
IPO date2010-03-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.